The PPRI Advisory Board was established to provide advice and guidance to the PPRI secretariat in its vision, management and performance of PPRI-related activities. It aims to promote information exchange between representatives of international and national authorities and agencies working in the pharmaceutical policy field (in particular in the area of pharmaceutical pricing and reimbursement).
Members of the Advisory Board are experts who have been members in the PPRI network for at least two years and who represent European and international institutions as well as national competent authorities for pharmaceutical pricing and reimbursement.
As of 2024, members of the PPRI Advisory Board are:
- Federal Ministry of Social Affairs, Health, Care and Consumer Protection
- European Commission, DG Santé
- OECD
- WHO Headquarters
- WHO Regional Office for Europe
- Patented Medicine Prices Review Board, Canada
- Estonian Health Insurance Fund, Estonia
- EOPYY-National Organization for the Provision of Healthcare Services, Greece
- INFARMED - National Authority of Medicines and Health Products, I.P., Portugal
- TLV - Dental and Pharmaceutical Benefits Agency, Sweden
For further information see 'Tasks and Procedures of the PPRI Advisory Board'.